ARTICLE | Product Development
Regeneron data show signs of activity with a new ovarian tumor target, and solidify company’s PD-1 position in skin cancer
By Lauren Martz, Executive Director, Biopharma Intelligence
October 26, 2023 1:12 AM UTC
Innovation in ovarian cancer targets was an emerging theme running through early-stage data presented at the ESMO 2023 Congress, and Regeneron was among the small but notable set of companies presenting data on a new tumor antigen for the challenging indication.
At the meeting, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) presented data from a Phase I dose-escalation study of ubamatamab (REGN4018), a MUC16 x CD3 bispecific in development to treat recurrent ovarian cancer…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/650393/regeneron-adds-to-ovarian-cancer-target-innovation-at-esmo